Wellington Management Group’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Sell
53,363
-1,180
-2% -$23.5K ﹤0.01% 1667
2025
Q4
$901K Sell
54,543
-4,691
-8% -$79.2K ﹤0.01% 1731
2025
Q3
$860K Sell
59,234
-5,605,499
-99% -$80.5M ﹤0.01% 1805
2025
Q2
$79.2M Sell
5,664,733
-5,744,865
-50% -$80.9M 0.01% 586
2025
Q1
$155M Buy
11,409,598
+1,561,647
+16% +$29.9M 0.03% 413
2024
Q4
$201M Sell
9,847,951
-879,499
-8% -$22.5M 0.04% 367
2024
Q3
$312M Buy
10,727,450
+903,683
+9% +$22.4M 0.05% 296
2024
Q2
$228M Buy
9,823,767
+1,553,818
+19% +$29.8M 0.04% 349
2024
Q1
$170M Buy
8,269,949
+995,232
+14% +$18.7M 0.03% 422
2023
Q4
$156M Sell
7,274,717
-14,243
-0.2% -$282K 0.03% 447
2023
Q3
$150M Buy
7,288,960
+250,784
+4% +$6.36M 0.03% 436
2023
Q2
$208M Buy
7,038,176
+1,837,716
+35% +$51.7M 0.04% 380
2023
Q1
$120M Buy
5,200,460
+78,730
+2% +$2.17M 0.02% 501
2022
Q4
$142M Buy
5,121,730
+5,100,036
+23,509% +$152M 0.03% 455
2022
Q3
$666K Buy
+21,694
New +$705K ﹤0.01% 1725
2018
Q1
Sell
-14,558
Closed -$228K 2219
2017
Q4
$228K Buy
+14,558
New +$262K ﹤0.01% 2168

Other funds holding DNLI

Wellington Management Group's DNLI Position: Q1 2026 in Review

Wellington Management Group reduced its Denali Therapeutics (DNLI) stake by 2.2% in Q1 2026, selling an estimated $23.5K and leaving 53,363 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

Wellington Management Group first reported a position in DNLI in Q4 2017 and has held it in 16 quarters since. The position peaked at $312M in Q3 2024. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Wellington Management Group held 53,363 shares of Denali Therapeutics worth $1.02M as of Q1 2026.
  • Wellington Management Group sold 1,180 Denali Therapeutics shares in Q1 2026, an estimated $23.5K.
  • Denali Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1667 holding.
  • Wellington Management Group first reported a position in Denali Therapeutics in Q4 2017 and has held it in 16 quarters since.
  • Wellington Management Group's Denali Therapeutics position peaked at $312M in Q3 2024.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.